Panel recommends Vioxx return to market in Canada

A medical advisory panel in Canada recommended Merck's painkiller Vioxx be allowed back on the market despite some cardiovascular risk, and also said Pfizer's Celebrex should remain on the market. The panel recommended Pfizer's other arthritis drug, Bextra, also a Cox-2 inhibitor, be kept off the market, and said ibuprofen pain relievers, currently sold OTC, should be subject to restrictions. Health Canada must now decide whether to accept the panel's recommendations.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health